Business
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint) First five patients with available data from six-month follow-up and biopsy show encouraging trend for Sensitivity and Specificity (secondary objective) Company to host webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.) SYDNEY, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, “Radiopharm” o
About this update from Radiopharm Theranostics Limited
[{"type":"image","alt":"Radiopharm Theranostics","displaySize":"","headline":null,"caption":"Radiopharm Theranostics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tTMhJ6Dxd3hW5bMDZRTgCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b","width":300,"height":110}},"lazy":false},{"type":"text","content":"90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint)","length":129,"tagName":"p"},{"type":"text","content":"First five patients with available data from six-month follow-up and biopsy show encouraging trend for Sensitivity and Specificity (secondary objective)","length":152,"tagName":"p"},{"type":"text","content":"Company to host webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.)","length":113,"tagName":"p"},{"type":"text","content":"SYDNEY, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the second interim data from twenty patients in its U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases. RAD 101 is Radiopharm’s novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins.","length":631,"tagName":"p"},{"type":"text","content":"The second interim analysis showed that 90% (18/20) of the patients dosed with RAD101 achieved concordance between PET imaging and MRI (the primary endpoint). The results showed significant and selective tumor uptake in the brain metastases. Images confirm metabolic activity in brain metastases compared to equivocal MRI findings.","length":331,"tagName":"p"},{"type":"text","content":"In addition, the first five patients with evaluable six-month follow-up and/or biopsy data show a positive trend for sensitivity and specificity (the secondary objectives). Sensitivity and specificity are...